@carlies, as you already know KRAS G12D is fairly rare. KRAS is altered in 29.61% of non-small cell lung carcinoma patients. G12C, G12D and G12R are some of the most common KRAS mutations, based on the specific mutations that are present. KRAS G12D is present in 4.26% of all non-small cell lung carcinoma patients.

Unfortunately, KRAS mutations have long been considered impossible to treat with drugs, but researchers have made recent breakthroughs in developing targeted therapies with promising results in some tumor types. For example, for people with KRAS mutation G12C, the Food and Drug Administration (FDA) granted accelerated approval to the first KRAS-blocking drug, called sotorasib (Lumakras). Under the new approval, sotorasib can be used to treat people with non-small cell lung cancer (NSCLC) that has spread nearby (locally advanced) or to distant locations (metastatic) in the body. Patients must have previously received at least one other systemic cancer treatment, such as chemotherapy, and have a particular KRAS mutation, known as G12C, in their tumors.
- FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as Milestone https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-sotorasib-lung-cancer-kras

This clinical trial results are currently under review.
- A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D.: https://clinicaltrials.gov/ct2/show/NCT01833143

You might ask your oncologist if they know more about the preliminary results and if a phase 3 trial is being planned. Have you talked to your oncologist about possible clinical trials that you may be eligible for?